Cardiovascular events during differing hypertension therapies in patients with diabetes

Journal of the American College of Cardiology
Michael A WeberACCOMPLISH Investigators

Abstract

The aim of this study was to determine which combination therapy in patients with hypertension and diabetes most effectively decreases cardiovascular events. The ACCOMPLISH (Avoiding Cardiovascular Events Through COMbination Therapy in Patients Living With Systolic Hypertension) trial compared the outcomes effects of a renin-angiotensin system blocker, benazepril, combined with amlodipine (B+A) or hydrochlorothiazide (B+H). A separate analysis in diabetic patients was pre-specified. A total of 6,946 patients with diabetes were randomized to treatment with B+A or B+H. A subgroup of 2,842 diabetic patients at very high risk (previous cardiovascular or stroke events) was also analyzed, as were 4,559 patients without diabetes. The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for angina, resuscitated arrest, and coronary revascularization. In the full diabetes group, the mean achieved blood pressures in the B+A and B+H groups were 131.5/72.6 and 132.7/73.7 mm Hg; during 30 months, there were 307 (8.8%) and 383 (11.0%) primary events (hazard ratio [HR]: 0.79, 95% confidence interval [CI]: 0.68 to 0.92, p = 0.003). For the diabetic patients at very high risk, there were 195 ...Continue Reading

References

Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Nov 13, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN CAMELOT Investigators
Dec 5, 2008·The New England Journal of Medicine·Kenneth JamersonUNKNOWN ACCOMPLISH Trial Investigators

❮ Previous
Next ❯

Citations

Jan 15, 2011·Current Atherosclerosis Reports·Gianpaolo ReboldiPaolo Verdecchia
Apr 19, 2013·Current Hypertension Reports·Colleen Flynn, George L Bakris
Nov 17, 2010·Nature Reviews. Cardiology·Rhonda M Cooper-DeHoffCarl J Pepine
Oct 9, 2013·Nature Reviews. Endocrinology·Daniel FinebergMark E Cooper
Feb 1, 2011·Nature Reviews. Nephrology·Luis M Ruilope
Jun 24, 2011·European Heart Journal·Peter S Sever, Franz H Messerli
Jun 16, 2012·International Journal of Clinical Practice·B N MercerM T Kearney
Aug 3, 2011·Advances in Therapy·Alejandro de la Sierra, Jorge Salazar
Dec 20, 2012·Wiener klinische Wochenschrift·Guntram SchernthanerUNKNOWN Ausrian Diabetes Association
Sep 18, 2013·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Marcus SchultzSverre Erik Kjeldsen
Dec 25, 2012·Expert Review of Cardiovascular Therapy·Antonio CocaAlexandre Roca-Cusachs I Coll
Jan 20, 2016·Expert Review of Cardiovascular Therapy·Daniel T LacklandAndrea D Boan
Jun 22, 2012·Annals of Medicine·Noël C Barengo, Jaakko O Tuomilehto
Dec 31, 2014·Journal of the Chinese Medical Association : JCMA·Chern-En ChiangShing-Jong Lin
May 2, 2014·Advances in Chronic Kidney Disease·Hala YamoutGeorge L Bakris
Mar 4, 2014·Endocrinology and Metabolism Clinics of North America·Guido LastraJames R Sowers
Jun 27, 2013·Journal of the American Society of Hypertension : JASH·Bertrand N Mukete, Clive Rosendorff
May 16, 2014·Canadian Journal of Diabetes·Richard E GilbertVincent Woo
May 16, 2014·Canadian Journal of Diabetes·Graydon S MeneillyDaniel Tessier
Jan 25, 2011·Cardiology Clinics·Sundararajan Srikanth, Prakash Deedwania
Mar 1, 2016·Nature Reviews. Nephrology·Michael A Weber, Daniel T Lackland
Jan 27, 2012·The Journal of Clinical Hypertension·Mariana Garcia-Touza, James R Sowers
Apr 7, 2011·The Journal of Clinical Hypertension·Shannon D SullivanRobert Ratner
May 16, 2015·European Heart Journal·William S WeintraubStuart Pocock
Apr 8, 2016·Wiener klinische Wochenschrift·Guntram SchernthanerBruno Watschinger
Apr 23, 2015·Current Cardiology Reports·Luke J Laffin, George L Bakris
Aug 13, 2011·Journal of the American College of Cardiology·Javier Sanz, Valentin Fuster
Jan 22, 2011·Journal of the American College of Cardiology·Anthony N DeMariaSotirios Tsimikas
Dec 5, 2014·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shokei Kim-MitsuyamaUNKNOWN OSCAR Study Group
May 26, 2016·Future Cardiology·Margarita Saiz Satjes, Francisco J Martinez-Martin
Jul 20, 2016·Best Practice & Research. Clinical Endocrinology & Metabolism·Samuel Horr, Steven Nissen
Dec 17, 2016·Diabetes Care·UNKNOWN American Diabetes Association
Apr 29, 2011·American Journal of Hypertension·Ehud Grossman, Franz H Messerli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.